San Diego-based Apricus Biosciences is finding
solutions for unmet medical needs. The pharmaceutical company is focused on
enhancing sexual health and, specifically, targeting the untreated erectile
dysfunction market. The company’s lead offering, Vitaros, is a topical cream
for the treatment of erectile dysfunction. The product was designed for direct
application and to provide a rapid onset with significant efficacy and a
favorable safety profile. Men who are resistant to taking oral medication or
have diseases that may preclude them from other treatments now have an
alternative with Vitaros.
Vitaros has been studied in more than 3,000
patients and demonstrated favorable, clinically meaningful responses in
measures of erectile function. Because men with erectile dysfunction often have
other diseases, Vitaros was also evaluated in men with accompanying diseases
like diabetes and cardiovascular disease. They also had clinically meaningful
and enhanced erectile function with the cream and tolerated Vitaros well.
The topical cream has now been approved for
use in Canada and Europe and will be brought to market by Apricus’ marketing
partners, including Abbott Laboratories Limited, Takeda Pharmaceuticals
International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati
S.p.A.), Bracco S.p.A. and Laboratoires Majorelle.
Apricus has two other product candidates as
well:
• Femprox,
a treatment for female sexual interest or arousal disorder; and
• RayVa,
a potential first-in-class topical cream treatment for Raynaud’s Phenomenon
Secondary to Scleroderma.
Apricus is committed to developing new,
fast-acting men’s and women’s health therapies, therapies that would appeal to
large patient populations struggling with unmet medical needs and improve their
quality of life. The company’s plan is to develop and bring its products to
market through partnerships with world-class pharmaceutical companies who share
its passion for providing life-improving treatments to patients and have proven
success in their markets as well as an established commercial presence.
For more information, visit www.apricusbio.com
About
MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
